Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health

Calgary, Alberta –News Direct–Universal Ibogaine Inc.

Calgary, AB – TheNewswire – June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO), (OTC:IBOGF) and (FSE:JC4) (“UI” or the “Company”), a life sciences company life with a mission to transform addiction treatment using medicalized ibogaine and a global licensing model is pleased to announce that Nick Karos, CEO, will be presenting at the HC Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. The event is a hybrid online and in-person event scheduled for June 27, 2022.

About H. C. Wainwright

HC Wainwright & Co is one of the oldest and most trusted names in corporate finance in the US providing investment banking, corporate advisory, research and analysis covering sectors including health and life sciences, mining, clean technology, transportation maritime and technology.

HC Wainwright hosts a robust calendar of conferences and events in the health sector. You can find more information and registration for the 1st Annual Mental Health Conference here.

Nick Karos, CEO of Universal Ibogaine, commented: “HC Wainwright is a leader in the space and could be a strong strategic partner in our ongoing corporate finance roadmap. The opportunity to tell our story to this audience is another important step in developing brand and offering awareness.

Correction Notice June 13 Blue Digital Media

In UI’s press release dated June 13, 2022, it was stated that stock options to be awarded to investor relations advisory firm Blue Digital Media would vest one-third at the end of each month in the service period of 3 months. Per TSXV Exchange Policy 4.4 Value-Based Compensation, stock options for investor relations firms must be granted quarterly over a 12-month period with the first vesting of 25% of the options at 3 months on the 25th. % at 6 months, 25% at 9 months and the final 25% at 12 months.

Netflix releases trailer for Stutz, Jonah Hill's documentary on mental health – Film Stories

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately use that protocol globally. worldwide through planned future license agreements. UI is simultaneously developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Center that, when combined with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and dramatically improve the lives of individuals and families affected by addiction. .

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE TSX VENTURE EXCHANGE POLICIES) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎

This press release may contain forward-looking information and statements. Forward-looking information is often characterized by words such as “plans,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “schedule,” “potential,” or others. similar words, or statements that certain events or conditions “may”, “should” or “could” occur. Forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, forward-looking statements should not be unduly relied upon because UI cannot guarantee that they will prove to be correct.

Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently expected due to a number of factors and risks, including, but not limited to, risks that required regulatory approvals may not be obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to the conditions as of the date hereof. UI undertakes no obligation to publicly disclose any revision of the forward-looking information contained herein to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unforeseen events, except as required by applicable securities laws. . ‎

Should you drink water on an empty stomach in the morning or after eating something?

For more information:

Investor Relations: Dugan Selkirk, IR Manager

[email protected]